Cadrenal Therapeutics (CVKD) Change in Accured Expenses (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Change in Accured Expenses of -$697176.0 for Q1 2026, down 450.75% sequentially from $198770.0 in Q4 2025, and down 12.5% YoY from -$796749.4 in Q1 2025.
Cadrenal Therapeutics (CVKD) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Change in Accured Expenses for 5 years, with the latest figure at -$697176.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 12.5% year-over-year to -$697176.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$321621.0 (down 365.83% YoY) and the FY2025 annual result came in at -$244171.0, down 144.94% from the prior year.
- Change in Accured Expenses fell to -$697176.0 in Q1 2026 per CVKD's latest filing, from $198770.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $499481.0 in Q4 2022 and troughed at -$697176.0 in Q1 2026.
- A 5-year average of $14112.6 and a median of $117083.0 in 2022 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses slumped 616.68% in 2023, then soared 1838.24% in 2024.
- Over 5 years, Change in Accured Expenses stood at $499481.0 in 2022, then tumbled by 51.69% to $241290.0 in 2023, then jumped by 71.41% to $413603.0 in 2024, then slumped by 51.94% to $198770.0 in 2025, then slumped by 450.75% to -$697176.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$697176.0, $198770.0, and -$45361.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cadrenal Therapeutics | 4.59 Mn | 2.19 Mn | - | 333,641.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 333,641.00 |
| Jun 30, 2026 | 333,641.00 |
| Mar 31, 2026 | -697,176.00 |
| Mar 31, 2026 | -697,176.00 |
| Dec 31, 2025 | 198,770.00 |
| Dec 31, 2025 | 198,770.00 |
| Sep 30, 2025 | -45,361.00 |
| Sep 30, 2025 | -45,361.00 |
| Jun 30, 2025 | 222,146.00 |
| Jun 30, 2025 | 222,146.00 |
| Mar 31, 2025 | -619,726.00 |
| Mar 31, 2025 | -619,726.00 |
| Dec 31, 2024 | 413,603.00 |
| Dec 31, 2024 | 413,603.00 |
| Sep 30, 2024 | 71,284.00 |
| Sep 30, 2024 | 71,284.00 |
| Jun 30, 2024 | 255,828.00 |
| Jun 30, 2024 | 255,828.00 |
| Mar 31, 2024 | -197,431.00 |
| Mar 31, 2024 | -197,431.00 |